Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Haruka Ebi , Masafumi Funamoto , Yoichi Sunagawa , et al Added: 3 years ago
Young Investigator Award Topic: 3. Heart Failure and Cardiomyopathy Introduction and Objectives Maladaptive hypertrophy is being recognized as a critical event during the development of heart failure. We screened natural compounds purified from fruits library and found that Nobiletin, contained in the peel of Citrus depressa, represses phenylephrine-induced hypertrophic responses in… View more

Heart Failure
THT 24: The ALT FLOW Early Feasibility Study
Author(s): Firas Zahr Added: 1 month ago
THT 24 - We are joined by Dr Firas Zahr (OHSU Knight Cardiovascular Institute Cardiology Clinic, US) to discuss the findings from the ALT FLOW Early Feasibility study (NCT03523416).The ALT FLOW Early Feasibility study aims to assess the initial clinical safety, functionality and effectiveness of a transcatheter atrial shunt system created by Edwards. 75 patients with symptomatic heart failure… View more

Heart Failure

Intervention
Author(s): Rocio Hinojar , Eike Nagel , Valentina O Puntmann Added: 3 years ago
Myocarditis is difficult to diagnose due to its heterogeneous clinical presentation. Patients often present with nonspecific symptoms and there is no easy-to-use and widely available diagnostic test. Although the clinical manifestations of myocarditis are heterogeneous, up to one-third of cases progress toward dilated cardiomyopathy (DCM).1,2 Myocarditis is a major cause of DCM, which is a… View more

Imaging & Diagnostics

Electrophysiology & Arrhythmia
Author(s): Pablo Avanzas Added: 3 years ago
It is a great pleasure for me to introduce the International Society of Cardiovascular Pharmacotherapy (ISCP) section on cardiovascular pharmacotherapy. This issue features a variety of excellent manuscripts on intriguing topics, including the anti-inflammatory effects of curcumin, the effects of statins on T-cell function in acute coronary syndrome in Asian populations, and the cost… View more

Prevention & Chronic Conditions

MI/ACS
Author(s): Mai Genpei , Yoichi Sunagawa , Masafumi Funamoto , et al Added: 3 years ago
Topic: 3. Heart Failure and Cardiomyopathy Introduction and Objectives Hemodynamic stimuli such as hypertension and myocardial infarction activate an intracellular signaling pathway, finally reach the nuclei of cardiomyocytes, change the pattern of hypertrophic response gene expressions, and induced cardiac hypertrophy and systolic dysfunction. These eventually lead to the development of… View more

Heart Failure

Heterogeneous Populations
Author(s): Mathias Goyen Added: 3 years ago
Atherosclerosis is a generalised disease and contributes to cardiac death, stroke, limb loss and a range of other illnesses. Disease in the major arteries, including the infra-renal abdominal aorta, internal iliac arteries, renal arteries and peripheral vasculature, remains a major cause of morbidity and mortality. For example, the prevalence of disease in the infra-renal abdominal aorta ranges… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Author(s): Gheorghe-Andrei Dan , Adrian Catalin Buzea Added: 3 years ago
Non-antivitamin K oral anticoagulants (NOACs) are no longer ‘new’ drugs: they already are established. Since randomised controlled trials (RCTs) usually enrol highly selected patient populations, the best way to demonstrate new drug efficiency/cost-effectiveness is to use long-term and ‘real-world’ data. In order to understand the NOAC experience in real life properly, one must first understand… View more

Anticoagulation

Electrophysiology & Arrhythmia
ESC 23: Economic Burden of CVD in the EU
Author(s): Ramón Luengo-Fernández Added: 7 months ago
ESC 2023 — Dr Ramón Luengo-Fernández (University of Oxford, UK) joins us on-site to discuss the findings from a registry which aimed to analyse the economic burden of cardiovascular disease within the EU. This was the first study to utilise Europe-wide patient registries and included the costs of long-term social care. Results from the registry found that cardiovascular disease cost the EU €282… View more

Standards & Guidelines
Highlights from the ESC Congress 2021
Author(s): Giulia Ferrannini , Gianluigi Savarese Added: 1 year ago

Heart Failure

Electrophysiology & Arrhythmia
Asymptomatic Left Ventricle Systolic Dysfunction
Author(s): Jaskanwal D Sara , Takumi Toya , Riad Taher , et al Added: 3 years ago
Heart failure (HF) affects more than 6 million people in the US and results in more than 1 million hospitalisations per year.1 In patients aged ≥65 years, there are more hospitalisations for a primary diagnosis of HF than any other condition.2 HF is a debilitating illness, associated with significant morbidity and mortality, rehospitalisation and societal costs.3 Current guidelines and position… View more

Heart Failure